Related references
Note: Only part of the references are listed.Connective tissue growth factor: Context-dependent functions and mechanisms of regulation
Iwona Cicha et al.
BIOFACTORS (2009)
Development of vorinostat: Current applications and future perspectives for cancer therapy
Victoria M. Richon et al.
CANCER LETTERS (2009)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Marwan G. Fakih et al.
CLINICAL CANCER RESEARCH (2009)
Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
Tai-Lung Cha et al.
CLINICAL CANCER RESEARCH (2009)
Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression
Junko Suzuki et al.
CLINICAL CANCER RESEARCH (2009)
Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion
Maria V. Barbolina et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
William Fazzone et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines
Michael B. Prystowsky et al.
JOURNAL OF PATHOLOGY (2009)
Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
Wei Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models
Todd M. Pitts et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
Q-L Zhang et al.
LEUKEMIA (2009)
Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage
Peter M. Wilson et al.
NUCLEIC ACIDS RESEARCH (2009)
Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFκB transcription factors
Jolyon Terragni et al.
BMC CELL BIOLOGY (2008)
Gene microarray analysis of human renal cell carcinoma The effects of HDAC inhibition and retinoid treatment
Trisha S. Tavares et al.
CANCER BIOLOGY & THERAPY (2008)
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer
Xu-Hui Zhang et al.
CANCER BIOLOGY & THERAPY (2008)
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Jennifer S. Carew et al.
CANCER LETTERS (2008)
Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling
Rama Pai et al.
CANCER RESEARCH (2008)
The role of histone deacetylases in prostate cancer
Ata Abbas et al.
EPIGENETICS (2008)
An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1
Christin L. Hanigan et al.
GASTROENTEROLOGY (2008)
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
L. Marquard et al.
HISTOPATHOLOGY (2008)
CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A
Jung-Hoon Kang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
Andrew J. Wilson et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma
Cristina Ferrario et al.
LABORATORY INVESTIGATION (2008)
Novel opportunities for thymidylate metabolism as a therapeutic target
Peter M. Wilson et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J. Frew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment
Sumiyasu Ishii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Histone deacetylase inhibitors induce mitotic slippage
F. E. Stevens et al.
ONCOGENE (2008)
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
Arthur Edwards et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
Anthony Tumber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Metallothionein: An overview
N. Thirumoorthy et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Ju-Hee Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphornas
Leon Bernal-Mizrachi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
NF kappa B pathway: A good signaling paradigm and therapeutic target
Vinay Tergaonkar
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Acetylation and deacetylation of non-histone proteins
MA Glozak et al.
GENE (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MT1G hypermethylation is associated with higher tumor stage in prostate cancer
R Henrique et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gene expression profiling in mitochondrial disease: assessment of microarray accuracy by high-throughput Q-PCR
KB Beckman et al.
MITOCHONDRION (2004)
Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data
C Pilarsky et al.
NEOPLASIA (2004)
The cellular geography of aurora kinases
M Carmena et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
BM Bolstad et al.
BIOINFORMATICS (2003)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
S Giacchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
